{
    "clinical_study": {
        "@rank": "79142", 
        "brief_summary": {
            "textblock": "To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's\n      sarcoma patients who have no remaining treatment options other than DOX-SL or patients who\n      have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is\n      medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with\n      Kaposi's sarcoma who have previously received systemic chemotherapy with or without an\n      anthracycline."
        }, 
        "brief_title": "Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive DOX-SL every 3 weeks for up to 20 cycles."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  AIDS-related Kaposi's sarcoma that requires systemic chemotherapy.\n\n          -  EITHER a medical indication for continuation of DOX-SL following treatment on another\n             DOX-SL protocol, OR no remaining treatment options other than DOX-SL.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior anthracyclines.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Cardiac ejection fraction < 50 percent or clinically significant cardiac disease.\n\n          -  Eligibility for a Liposomal Technology comparative protocol.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other cytotoxic chemotherapy.\n\n        Patients with the following prior condition are excluded:\n\n        History of idiosyncratic or allergic reaction to anthracyclines.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Chemotherapy within the past 3 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002147", 
            "org_study_id": "134D", 
            "secondary_id": "LTI-30-25"
        }, 
        "intervention": {
            "intervention_name": "Doxorubicin hydrochloride (liposomal)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "keyword": [
            "Sarcoma, Kaposi", 
            "Liposomes", 
            "Doxorubicin", 
            "Acquired Immunodeficiency Syndrome", 
            "Drug Carriers"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Menlo Park", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94025"
                }, 
                "name": "Sequus Pharmaceutical Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "citation": "Jablonowski H, Szelenyi H, Armbrecht C, Mauss S, Niederau C, Strohmeyer G. Liposomal doxorubicin--a new formulation for the treatment of Kaposi's sarcoma: a study on safety and efficacy in AIDS patients. Int Conf AIDS. 1993 Jun 6-11;9(1):397 (abstract no PO-B12-1573)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002147"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sequus Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1996"
    }, 
    "geocoordinates": {
        "Sequus Pharmaceutical Inc": "37.454 -122.182"
    }
}